Yale Cancer Center researchers identified a leading mechanism behind the pathophysiology of COVID-19, and pinpointed a biological marker for the mechanism that may help with treatment.
FDA joins Reagan-Udall, Friends of Cancer Research to form COVID-19 Diagnostics Evidence Accelerator
FDA is participating in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics. The accelerator is organized by the Reagan-Udall Foundation for FDA in collaboration with Friends of Cancer Research.
In a letter to House and Senate leaders, Research!America has asked for a massive boost in federal spending to address the damage the U.S. research organizations have sustained as a result of the COVID-19 pandemic.
Researchers in the U.K, Germany and the United States have developed an algorithm to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic.
FDA has issued warning letters to three companies for marketing adulterated and misbranded COVID-19 antibody tests.
Mount Sinai Health System is beginning the first clinical trial in the New York metropolitan region of an immune-boosting therapy in COVID-19 patients.
New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, could demonstrate why thoracic cancer patients experienced a high death rate of 33% when COVID-19 swept across Europe.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the U.K., Germany, and the U.S.
ChristianaCare has developed a virtual telehealth service that provides daily monitoring of employees for COVID-19 symptoms, testing, and care for employees who test positive.
A total of 1,066 patients have joined a HealthTree observational study on COVID-19 and multiple myeloma. All participating patients have filled out a HealthTree profile by contributing their de-identified health data and answered survey questions related to their outcomes during the COVID-19 pandemic.
